Crossmark

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Crossref DOI link: https://doi.org/10.1186/s40425-019-0611-3

Published Online: 2019-07-10

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dama, Paola http://orcid.org/0000-0001-5716-9665
Tang, Marshall

Fulton, Noreen

Kline, Justin

Liu, Hongtao
Funding

Funding for this research was provided by:

Bristol-Myers Squibb
License Information

Text and Data Mining valid from 2019-07-10
More Information

Article History

Received: 20 December 2018

Accepted: 6 May 2019

First Online: 10 July 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.